Shigeo Muro

Professor

Nara Medical University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Backgrounds Fibrosis may coexist with emphysema in chronic obstructive pulmonary disease (COPD), but computed tomography (CT) quantification is challenging. Persistent homology (PH), a topological data analysis technique, provides interpretable structural features in grayscale images. By using PH, this CT study aimed to quantify fibrotic lesions in nonemphysematous and emphysematous lungs and to investigate clinical implications of PH-based fibrosis quantification in patients with COPD. Methods The study included subjects from the Lung Cancer Screening (LCS) cohort (n=346) and two prospective COPD cohorts (Kyoto University [KU], n=234; Kyoto-Himeji, n=166). Based on CT value patterns and spatial topology, PH assigned each voxel as fibrotic or non-fibrotic and calculated the percentage of fibrotic lung volume (PH-fibrosis%) in association with visually identified interstitial lung abnormality (ILA) and COPD outcomes. Results Higher PH-fibrosis% was associated with ILAs in the LCS and KU cohorts. The two COPD cohorts consistently showed significant associations between higher baseline PH-fibrosis% and future exacerbation risk independent of emphysema and airway wall thickness (hazard ratios [HR]: 1.39 and 3.35 for KU and Kyoto-Himeji, respectively). In the KU cohort, higher PH-fibrosis% was significantly associated with increased mortality (HR: 1.94), with a similar trend in the Kyoto-Himeji cohort (HR: 1.86). Longitudinal increases in PH-fibrosis% over median 4.98 years were associated with higher exacerbation frequency and patients experiencing greater increase in PH-fibrosis% subsequently exhibited higher mortality in the KU cohort. Conclusions PH can be used to quantify fibrotic lesions on CT and PH-fibrosis% could be a prognostic imaging marker in patients with COPD.

Year:

2026

Background: Home oxygen therapy (HOT) is expected to enhance physical activity levels in patients with chronic respiratory failure by alleviating dyspnea. However, studies comparing physical activity levels before and after HOT initiation in the same patients are limited. The present study aims to objectively examine the effectiveness of HOT using a cloud-based home care system in patients with chronic respiratory failure. Methods: This prospective, multicenter, non-blinded, single-arm trial will enroll 30 patients with chronic respiratory failure scheduled to undergo HOT. Initiated on October 10, 2023, the study will conclude on September 30, 2025. Participants will receive oxygen concentrators equipped with usage-monitoring capabilities and dedicated pulse oximeters with an accelerometer function to measure oxygen saturation, pulse rate, and physical activity levels. Patients will be required to attach the pulse oximeter to their fingers at designated times to record pulse rates and percutaneous oxygen saturation values. Additionally, wearing the pulse oximeter around their necks will allow the accelerometer to measure physical activity levels. Beyond physical activity, factors such as dyspnea, quality of life, and depression will be evaluated before and after initiation of HOT. The primary outcome is the change in the monthly equivalent of daily calorie consumption before and 3 months after initiating HOT. Statistical analyses, including paired t tests, will be conducted to compare the mean and standard deviation of daily calorie consumption equivalence 1 month before and 3 months after HOT initiation. Discussion: The strength of the home oxygen therapy on the physical activity of daily living study will be its objective assessment of physical activity levels before and after initiating HOT. Additionally, we will evaluate the health-related quality of life.

Year:

2025

Chronic eosinophilic pneumonia (CEP) is an eosinophilic lung disease. Treatment for CEP includes corticosteroids; however, CEP often recurs. A 53‐year‐old woman was referred to our hospital because of poorly controlled asthma. She was treated with combination of moderate‐dose inhaled corticosteroid (ICS), a long‐acting β2‐agonist (LABA), and betamethasone/dexchlorpheniramine. She was switched to single‐inhaler triple therapy, after which her asthma control improved; thus, betamethasone/dexchlorpheniramine was discontinued. Ten weeks later, she was diagnosed with CEP due to marked eosinophilia and pulmonary eosinophilic infiltrates. Oral corticosteroid treatment was initiated, symptoms improved, and peripheral blood eosinophilia decreased with improved infiltrative shadows. Remission induction therapy was initiated with benralizumab combined with corticosteroid therapy. Eosinophilia and inflammatory responses decreased. After 7 months, corticosteroid was discontinued, and she was treated with benralizumab alone. She remained in remission for 4 months. This case suggests that benralizumab may be useful as a remission induction therapy in patients with CEP.

Year:

2024

Background Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β 2 -agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asthma diagnosis who experience frequent exacerbations and have blood eosinophil (EOS) count ≥ 300 cells/mm 3 , and in patients with COPD and asthma with continuing/worsening symptoms despite receiving dual ICS/LABA therapy. These post-hoc analyses of the KRONOS study in patients with COPD and without an asthma diagnosis, examine the effects of fixed-dose triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) versus dual therapies on lung function and exacerbations based on blood EOS count – focusing on blood EOS count 100 to 100 cells/mm 3 , even if disease severity is moderate and there is no recent history of exacerbations. Trial registration ClinicalTrials.gov registry number NCT02497001 (registration date, 13 July 2015).

Year:

2024

Sarcoidosis is a multisystemic granulomatous disease that is frequently localized in the lungs and lymph nodes. We herein report a case of pulmonary sarcoidosis secondary to shin'iseihaito administration. During remission with 5 mg prednisolone/day of maintenance treatment, chest computed tomography revealed a mass in the left lower lobe with re‐enlarged bilateral hilar/mediastinal lymph nodes. Transbronchial lung biopsy of the mass and endobronchial ultrasound‐guided transbronchial needle aspiration of mediastinal lymph nodes revealed adenocarcinoma and noncaseating granulomas, respectively. Based on these findings, the patient was diagnosed with sarcoidosis recurrence associated with lung cancer without cancer metastasis. We present the case of sarcoidosis recurrence associated with lung cancer after drug‐induced pulmonary sarcoidosis with lung injury. To our knowledge, this is the first report of sarcoidosis triggered by drug administration and lung cancer. Histological diagnosis of mediastinal lymphadenopathy with lung cancer is essential for differentiating metastasis from sarcoidosis.

Year:

2024

Severe asthma affects approximately 5%–10% of patients with asthma. Herein, we describe a case of non‐type 2 asthma that progressively worsened over the years. An 80‐year‐old woman was diagnosed with asthma 11 years back. She experienced repeated exacerbations requiring treatment with systemic corticosteroid despite therapy with medications including high‐dose inhaled corticosteroids/long‐acting beta‐agonists plus long‐acting muscarinic antagonist. The patient presented with non‐eosinophilic asthma. Therefore, the patient was initially treated with bronchial thermoplasty, which was effective for 1 year only. Treatment with bronchial thermoplasty, benralizumab, dupilumab, and mepolizumab was ineffective. The fourth treatment, which included tezepelumab, was initiated. The patient's symptoms and quality of life improved significantly. This is the first case of a patient who did not respond to sequential bronchial thermoplasty, benralizumab, dupilumab, and mepolizumab but who presented with good clinical response to tezepelumab. Therefore, tezepelumab may be useful for patients with non‐type 2 asthma.

Year:

2024

There have been several reports of drug‐induced lung injury caused by molecular‐targeted agents. Additionally, medical history of interstitial lung disease and chest irradiation are established risk factors for the development and progression of drug‐induced lung injury. Moreover, the presence of fibrosis on chest computed tomography before treatment is a predictive factor for the appearance of pneumonia induced by anticancer drugs. Accordingly, patients with a history of interstitial lung disease or pneumonitis were excluded from clinical trials of dabrafenib and trametinib combination therapy for patients with previously treated BRAF V600E ‐mutant metastatic non‐small‐cell lung cancer. This article presents a case of successful dabrafenib and trametinib combination therapy in a patient with BRAF V600E ‐mutant non‐small‐cell lung cancer who had a history of radiation pneumonitis and developed recurrence after conventional chemoradiotherapy.

Year:

2024

Collaborators (2)

NAOYA TANABE

Kyoto University Hospital

JAPAN
View details

Toyohiro Hirai

Kyoto University

JAPAN
View details